Hanson & Doremus Investment Management’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49K | Hold |
127
| – | – | 0.01% | 325 |
|
|
2026
Q1 | $37K | Sell |
127
-18
| -12% | -$5.92K | ﹤0.01% | 358 |
|
|
2025
Q4 | $51K | Sell |
145
-25
| -15% | -$8.45K | 0.01% | 320 |
|
|
2025
Q3 | $55K | Sell |
170
-6
| -3% | -$1.87K | 0.01% | 318 |
|
|
2025
Q2 | $68K | Hold |
176
| – | – | 0.01% | 294 |
|
|
2025
Q1 | $77K | Hold |
176
| – | – | 0.01% | 281 |
|
|
2024
Q4 | $65K | Hold |
176
| – | – | 0.01% | 282 |
|
|
2024
Q3 | $92K | Hold |
176
| – | – | 0.01% | 248 |
|
|
2024
Q2 | $95K | Hold |
176
| – | – | 0.02% | 247 |
|
|
2024
Q1 | $91K | Sell |
176
-19
| -10% | -$9.45K | 0.02% | 255 |
|
|
2023
Q4 | $92K | Sell |
195
-60
| -24% | -$27.7K | 0.02% | 250 |
|
|
2023
Q3 | $111K | Hold |
255
| – | – | 0.02% | 220 |
|
|
2023
Q2 | $113K | Hold |
255
| – | – | 0.02% | 222 |
|
|
2023
Q1 | $117K | Sell |
255
-128
| -33% | -$60.9K | 0.03% | 219 |
|
|
2022
Q4 | $196K | Hold |
383
| – | – | 0.04% | 183 |
|
|
2022
Q3 | $174K | Buy |
383
+108
| +39% | +$51.7K | 0.05% | 188 |
|
|
2022
Q2 | $133K | Hold |
275
| – | – | 0.03% | 215 |
|
|
2022
Q1 | $135K | Hold |
275
| – | – | 0.03% | 227 |
|
|
2021
Q4 | $127K | Buy |
275
+110
| +67% | +$46.3K | 0.03% | 229 |
|
|
2021
Q3 | $62K | Hold |
165
| – | – | 0.01% | 283 |
|
|
2021
Q2 | $44K | Hold |
165
| – | – | 0.01% | 273 |
|
|
2021
Q1 | $59K | Hold |
165
| – | – | 0.01% | 287 |
|
|
2020
Q4 | $53K | Hold |
165
| – | – | 0.01% | 278 |
|
|
2020
Q3 | $44K | Hold |
165
| – | – | 0.01% | 273 |
|
|
2020
Q2 | $43K | Hold |
165
| – | – | 0.01% | 275 |
|
|
2020
Q1 | $37K | Hold |
165
| – | – | 0.01% | 292 |
|
|
2019
Q4 | $50K | Hold |
165
| – | – | 0.01% | 291 |
|
|
2019
Q3 | $40K | Sell |
165
-35
| -18% | -$9.59K | 0.01% | 300 |
|
|
2019
Q2 | $56K | Hold |
200
| – | – | 0.02% | 268 |
|
|
2019
Q1 | $57K | Hold |
200
| – | – | 0.02% | 266 |
|
|
2018
Q4 | $53K | Hold |
200
| – | – | 0.02% | 261 |
|
|
2018
Q3 | $55K | Hold |
200
| – | – | 0.02% | 279 |
|
|
2018
Q2 | $48K | Hold |
200
| – | – | 0.02% | 300 |
|
|
2018
Q1 | $44K | Hold |
200
| – | – | 0.01% | 313 |
|
|
2017
Q4 | $45K | Hold |
200
| – | – | 0.02% | 309 |
|
|
2017
Q3 | $38K | Hold |
200
| – | – | 0.01% | 311 |
|
|
2017
Q2 | $38K | Hold |
200
| – | – | 0.01% | 301 |
|
|
2017
Q1 | $33K | Hold |
200
| – | – | 0.01% | 300 |
|
|
2016
Q4 | $28.8K | Hold |
200
| – | – | 0.01% | 303 |
|
|
2016
Q3 | $25K | Hold |
200
| – | – | 0.01% | 298 |
|
|
2016
Q2 | $26K | Hold |
200
| – | – | 0.01% | 286 |
|
|
2016
Q1 | $28K | Hold |
200
| – | – | 0.01% | 291 |
|
|
2015
Q4 | $28K | Hold |
200
| – | – | 0.01% | 307 |
|
|
2015
Q3 | $28K | Hold |
200
| – | – | 0.01% | 294 |
|
|
2015
Q2 | $33K | Hold |
200
| – | – | 0.01% | 292 |
|
|
2015
Q1 | $31K | Hold |
200
| – | – | 0.01% | 295 |
|
|
2014
Q4 | $25K | Hold |
200
| – | – | 0.01% | 318 |
|
|
2014
Q3 | $24K | Hold |
200
| – | – | 0.01% | 309 |
|
|
2014
Q2 | $22K | Hold |
200
| – | – | 0.01% | 314 |
|
|
2014
Q1 | $20K | Hold |
200
| – | – | 0.01% | 313 |
|
|
2013
Q4 | $18K | Hold |
200
| – | – | 0.01% | 312 |
|
|
2013
Q3 | $17K | Hold |
200
| – | – | 0.01% | 305 |
|
|
2013
Q2 | $16K | Buy |
+200
| New | +$15K | 0.01% | 289 |
|
Other funds holding ELV
Hanson & Doremus Investment Management's ELV Position: Q2 2026 in Review
Hanson & Doremus Investment Management held its Elevance Health (ELV) position steady in Q2 2026 at 127 shares worth $49K. The position accounts for 0.01% of the portfolio, ranked #325.
Hanson & Doremus Investment Management first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $196K in Q4 2022. 1,600 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Hanson & Doremus Investment Management held 127 shares of Elevance Health worth $49K as of Q2 2026.
- Hanson & Doremus Investment Management left its Elevance Health share count unchanged in Q2 2026.
- Elevance Health made up 0.01% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #325 holding.
- Hanson & Doremus Investment Management first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
- Hanson & Doremus Investment Management's Elevance Health position peaked at $196K in Q4 2022.
- 1,600 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.